Epsilogen
PrivateLast Round
Series B
Extension
Sep 9, 2024
Total Funding Raised
$74.64M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Epsilogen operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a Series B Extension round in September 2024.
Epsilogen is a biotechnology company that develops immunoglobulin E (IgE) antibodies for the treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Epsilogen Comparables
Compare Epsilogen with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alligator Bioscience | 77% | |
| Crescendo Biologics Ltd. | 77% | |
| IGM Biosciences | 76% |
For institutional investors. Book with your work email.
Epsilogen Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Sep 9, 2024 | ||||
| Series B | Mar 2, 2022 | ||||
| Grant | Oct 22, 2020 | ||||
| Grant | Jul 20, 2020 | ||||
| Series A Extension | Apr 20, 2020 | ||||
Grant | Apr 2, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Epsilogen Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| UK government | Grant |
| Epidarex Capital | Series B, Series A, Series A Extension, Series B Extension |
| 3B FUTURE Health Fund | Series B Extension, Series B |
| ALSA Ventures | Series B Extension, Series A, Series A Extension, Series B |
| British Patient Capital | Series B Extension, Series B |
| ALSA Holdings | Series B Extension, Series A, Series A Extension, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 65% MoM, reaching 1.8K.
- Oct 7, 2025
Cristina Oliva appointed as Chief Medical Officer.
For institutional investors. Book with your work email.
Epsilogen Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Epsilogen's valuation, stock price, and market status.
Is Epsilogen a public or private company?
Epsilogen is a private company.
What is the current stock price of Epsilogen?
Epsilogen is a private company, so its shares have no public market price. Caplight tracks Epsilogen's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Epsilogen worth (valuation)?
Valuation information for Epsilogen is not publicly available.
Can I buy Epsilogen stock?
Epsilogen shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Epsilogen's last funding round?
Epsilogen's most recent funding round was Series B Extension on September 9, 2024.
Who are the main investors in Epsilogen?
Key investors in Epsilogen include Innovate UK, Epidarex Capital.
Will Epsilogen IPO soon?
No public IPO plans have been announced for Epsilogen.
How can I track Epsilogen secondary market activity?
Caplight tracks bids, offers, and trades in Epsilogen's shares on secondary markets.